来那度胺(Lenalidomide) - 药物靶点：CK1α x CRBN x IKZF1 x IKZF3_在研适应症：大B细胞淋巴瘤，边缘区B细胞淋巴瘤，成人T细胞白血病/淋巴瘤_专利_临床

概要

基本信息

药物类型

降解型分子胶

别名

1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline、3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione、CMIO-LLD

+ [18]

靶点

CK1α x CRBN x IKZF1 x IKZF3

作用方式

抑制剂、调节剂、降解剂

作用机制

CK1α抑制剂(casein kinase 1 alpha 1 inhibitors)、CRBN调节剂(Cereblon蛋白调节剂)、IKZF1 降解剂(DNA结合蛋白IKAROS 降解剂)

治疗领域

肿瘤免疫系统疾病遗传病与畸形+ [7]

在研适应症

大B细胞淋巴瘤边缘区B细胞淋巴瘤成人T细胞白血病/淋巴瘤+ [63]

非在研适应症

Aase Smith综合征II型急性肾损伤急性白血病+ [128]

原研机构

Celgene Corp.

在研机构

Millennium Pharmaceuticals, Inc.

Bristol Myers Squibb Co.

Celgene Corp.

+ [29]

非在研机构

Janssen-Cilag International NV

依格斯（北京）医疗科技有限公司

Onyx Therapeutics, Inc.

+ [11]

权益机构

Starton Therapeutics, Inc.

Xencor, Inc.

Bend Bioscience LLC

+ [1]

最高研发阶段批准上市

首次获批日期

美国 (2005-12-27),

骨髓增生异常综合征

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、优先审评 (中国)、孤儿药 (日本)、特殊审批 (中国)

登录后查看时间轴

结构/序列

分子式C13H13N3O3

InChIKeyGOTYRUGSSMKFNF-UHFFFAOYSA-N

CAS号191732-72-6

关联

1,303

项与来那度胺相关的临床试验

NCT06348147

/ Suspended临床2期

An Attenuated Schedule Dara-RVd Induction for Patients With Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Stem Cell Transplantation

This Phase II hybrid decentralized trial will examine the effect of daratumumab-based quadruplet induction therapy administered at an attenuated schedule in subjects with newly diagnosed multiple myeloma (NDMM) who are eligible for standard-of-care autologous stem cell transplantation (ASCT). Daratumumab, lenalidomide, bortezomib, and dexamethasone (Dara-RVd) have recently become a standard induction regimen for patients with NDMM who are eligible for ASCT in the United States. As implemented in clinical trials, Dara-RVd involves twice weekly bortezomib administration, which is inconvenient for patients and may result in increased rates of limiting toxicity, such as peripheral neuropathy. Adoption of alternate schedules involving once-weekly bortezomib is common in real-world practice, however a paucity of prospective data supporting this practice exists.
This study examines the efficacy of an attenuated Dara-RVd schedule involving once-weekly bortezomib dosing.

开始日期2026-07-01

申办/合作机构

Lineberger Comprehensive Cancer Center

NCT07029776

/ Not yet recruiting临床2期

A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)

The purpose of this research is to learn whether using teclistamab and talquetamab at different time points will improve survival in participants with high-risk Multiple Myeloma (MM).
The treatment on this study will consist of Induction chemotherapy and stem cell collection, Immunotherapy 1 chemotherapy and Immunotherapy 2 chemotherapy. For participants whose testing show they are Minimal Residual Disease (MRD) positive (still have myeloma cells present in the bone marrow testing), a Melphalan-based stem cell transplant will be performed. For participants whose testing show they are MRD negative, the stem cell transplant will not be performed. All participants will go on to receive Immunotherapy 3 chemotherapy, Immunotherapy 4 chemotherapy, and Maintenance therapy.

开始日期2026-07-01

申办/合作机构

Janssen Research & Development LLC

NCT07428369

/ Not yet recruiting临床2/3期

A Phase 2/3, Open-Label, Randomized Study of Linvoseltamab, Bortezomib and Lenalidomide (Linvo-VR) With and Without Autologous Stem Cell Transplantation (ASCT) Vs Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Transplant-Eligible Participants With Newly Diagnosed Multiple Myeloma

This study is focused on participants with Newly Diagnosed Multiple Myeloma (NDMM) who are eligible for high dose chemotherapy followed by Autologous Stem Cell Transplantation (ASCT).
This study is evaluating a drug called linvoseltamab in combination with standard therapies for multiple myeloma called bortezomib (V) and lenalidomide (R). This combination is abbreviated as Linvo-VR.
The aim of this study is to compare how well Linvo-VR, with and without ASCT, treats myeloma to how well the current standard of care regimen for NDMM treats myeloma. That current standard of care regimen includes the drugs daratumumab (D), bortezomib (V), lenalidomide (R), and dexamethasone (d). This combination is referred to as DVRd. The study is also evaluating if Linvo-VR treats myeloma well enough that ASCT is no longer needed with the first myeloma treatments.
The study is looking at several other research questions, including:
* What side effects may happen from taking linvoseltamab
* How much linvoseltamab is in the blood at different times
* Whether the body makes antibodies against the linvoseltamab (which could make the drug less effective or could lead to side effects)

开始日期2026-06-05

申办/合作机构

Regeneron Pharmaceuticals, Inc.

100 项与来那度胺相关的临床结果

登录后查看更多信息

100 项与来那度胺相关的转化医学

登录后查看更多信息

100 项与来那度胺相关的专利（医药）

登录后查看更多信息

7,794

项与来那度胺相关的文献（医药）

2026-12-31·JOURNAL OF MEDICAL ECONOMICS

Indirect treatment comparison of DVRd plus DR maintenance (PERSEUS study) versus DVTd or VTd with or without lenalidomide maintenance in transplant-eligible patients with previously untreated multiple myeloma

Article

作者: He, Jianming ; Nair, Sandhya ; Einsele, Hermann ; Facon, Thierry ; Dimopoulos, Meletios A. ; Caillot, Denis ; Sonneveld, Pieter ; Zweegman, Sonja ; Ammann, Eric ; Nobrega, Marjorie ; Broijl, Annemiek ; Spencer, Andrew ; Perrot, Aurore ; Schjesvold, Fredrik ; Gay, Francesca ; Hajek, Roman ; Boccadoro, Mario ; Rodriguez-Otero, Paula ; Hulin, Cyrille ; Sitthi-Amorn, Anna ; Rowe, Melissa ; Leleu, Xavier ; Mina, Roberto

AIMS:

To compare the effectiveness of induction and consolidation with daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) plus maintenance therapy with daratumumab and lenalidomide (DR) with 2 treatment regimens that are widely used for transplant-eligible newly diagnosed multiple myeloma (TE NDMM): bortezomib, thalidomide, and dexamethasone (VTd) or daratumumab-VTd (DVTd) followed by observation (Obs) or lenalidomide maintenance.

MATERIALS AND METHODS:

Individual patient-level data from the PERSEUS (NCT03710603) and CASSIOPEIA (NCT02541383) trials were used to compare DVRd + DR with VTd + Obs and with DVTd + Obs. Inverse probability of treatment weighting was used to adjust for differences in baseline patient characteristics between the two trials; inverse probability of censoring weighting was used to adjust for the second randomization of CASSIOPEIA. Data from the CASSIOPEIA and Myeloma XI (EudraCT 2009-010956-93) trials were combined to model outcomes associated with lenalidomide (R) maintenance following induction with DVTd or VTd.

RESULTS:

DVRd + DR showed superior progression-free survival compared with DVTd + Obs (hazard ratio, 0.39 [95% CI = 0.26-0.59]), VTd + Obs (0.17 [95% CI = 0.12-0.25]), DVTd + R (0.62 [95% CI = 0.41-0.92]), and VTd + R (0.29 [95% CI = 0.18-0.43]). Sensitivity analyses showed results were consistent with the base case.

LIMITATIONS:

The indirect treatment comparison was unanchored due to a lack of common comparators and relied on external data from the Myeloma XI trial to model outcomes associated with DVTd or VTd followed by R maintenance. Despite best efforts to identify and adjust for important treatment effect modifiers, there is a potential for residual confounding.

CONCLUSIONS:

Findings from this study suggest that DVRd followed by DR maintenance offers superior survival outcomes compared with current standards of care in TE patients with NDMM.

2026-12-31·Hematology

Neutrophil extracellular trap-related genes in PTCL: identification, prognosis and drug interaction prediction via bioinformatics-machine learning

Article

作者: Chen, Jing ; Cheng, Fanjun ; Fang, Jun

OBJECTIVE:

This study aimed to identify neutrophil extracellular trap-related genes (NET-RGs), explore their prognostic significance, and predict drug interactions in peripheral T-cell lymphoma (PTCL).

METHODS:

Differentially expressed NET-RGs (DE-NRGs) between PTCL and normal tissues were screened. Functional enrichment analysis was conducted. Bioinformatics and machine learning were used to identify hub genes and assess their diagnostic value. Univariate and multivariate analyses were used to evaluate prognostic roles. Correlation and immune infiltration analyses were performed to explore relationships with the tumor microenvironment (TME). Clinical data were collected from PTCL patients who received potential agents (lenalidomide) as first-line treatment.

RESULTS:

A total of 31 DE-NRGs were identified (18 upregulated and 13 downregulated), enriched in inflammatory response, extracellular matrix organization, and infection involvement. Four hub genes (AKT2, MAPK14, IRF1, and TNF) were identified as effective PTCL diagnostic markers. Higher AKT2/MAPK14 expression correlated with poorer overall survival (OS), while elevated TNF expression associated with better OS; AKT2 and TNF independently predicted OS. These genes were implicated in modulating TME remodeling. Potential therapeutic agents (e.g. capivasertib, lenalidomide) were predicted, and lenalidomide may represent a feasible initial treatment option for PTCL, with an objective response rate (ORR) of 40.0% and a maximum survival duration exceeding 50 months.

CONCLUSION:

NET-RGs play crucial roles in diagnosis, prognosis, and TME regulation, and lenalidomide, a putative TNF-targeting agent, may represent a feasible initial treatment option in PTCL.

2026-12-01·JOURNAL OF MOLECULAR MEDICINE-JMM

Anti-myeloma activity of the CXCR4 antagonist WZ811

Article

作者: Suroviakova, Katarina ; Sedlak, Jan ; Jakubikova, Jana ; Valuskova, Zuzana ; Strizova, Anna ; Marinkovicova, Maria Elisabeth ; Csicsatkova, Nikoleta ; Cholujova, Danka

Abstract:

The CXCR4-CXCL12 axis is crucial for the interaction between malignant plasma cells (PC) and their microenvironment in multiple myeloma (MM). Here, we show that CXCR4 expression is upregulated in MM cell lines and PCs during both premalignant and active stages of MM, compared to normal PCs from healthy donors. The CXCR4 antagonist WZ811 reduced the viability of MM PCs and cell lines, while tumor microenvironment cells from both MM patients and healthy donors exhibited significant resistance. In vivo, WZ811 significantly reduced tumor burden and improved survival. WZ811-mediated MM cell death involved disruption of mitochondrial transmembrane potential, externalization of transmembrane phosphatidylserine, activation of caspases, increased levels of autophagic proteins, and an increase in G 0 /G 1 phase of the cell cycle. WZ811 also eliminated the MM stem cell-like side population, though slight resistance was observed with stromal cells. Additionally, WZ811 increased levels of CXCL12 and extracellular matrix molecules collagen IV and laminin in MM cells. Combining WZ811 with anti-MM agents showed synergism with doxorubicin, dexamethasone, bortezomib, lenalidomide, and pomalidomide, while antagonism was observed with carfilzomib, supporting the clinical assessment of WZ811 in MM.

Key messages:

WZ811 reduced the viability of myeloma primary cells and cell lines.WZ811 reduced tumor burden and improved survival in vivo xenograft model.WZ811 mechanisms involved apoptotic and autophagic cell death.WZ811 eliminated the MM stem cell-like side population.WZ811 synergized with DOX, DEX, BTZ, LEN, and POM.

2,896

项与来那度胺相关的新闻（医药）

2026-04-03

·活力张江

【第五期】张江发促会会员动态简报

会员动态 01 恒瑞医药：重磅公布： 2026年美国皮肤病学会（AAD）年会于近日在美国科罗拉多州丹佛隆重召开。恒瑞医药自主研发的全球首创双靶点IL-23p19和IL-36R的创新药SHR-1139用于中重度斑块状银屑病患者I期研究数据重磅发布。 2026 AAD︱恒瑞医药全球首创IL-23p19/IL-36R双靶点抗体SHR-1139用于中重度斑块状银屑病患者I期研究数据重磅公布 02 美迪西：战略合作： 3月30日，上海美迪西生物医药股份有限公司与扬子江药业集团全资子公司上海海路生物技术有限公司正式举行战略合作签约仪式。双方将在新药临床前研发、项目出海与引进等领域开展深度协同。提速新药研发，赋能新药出海！美迪西与扬子江药业集团海路生物达成战略合作 03 益临思： ‌SAB成立： 2026年3月26日，益临思科学顾问委员会（SAB）成立暨重点项目医学转化闭门研讨会在上海顺利举行。本次会议由上海益临思医药开发有限公司主办，聚焦构建高水平医学转化平台、提升注册策略与临床设计能力。聚智启新，共促医药研发转化！益临思科学顾问委员会（SAB）正式成立！ 04 妙文创意：考察交流： 3月31日，山东省新闻工作者协会、山东省报业协会、大众报业集团联合组织开展“人工智能+”赋能新闻宣传高质量发展学习调研，在沪期间，调研团专赴妙文创意科技上海总部考察交流。妙文·友 | 山东省新闻系统调研团到访妙文创意科技 05 蓝帆医疗：独家代理：近日，蓝帆医疗与国内领先的医学影像创新企业南京沃福曼医疗科技有限公司达成国际国内进一步合作，蓝帆医疗正式成为沃福曼全部血管内光学断层成像（OCT）产品线在亚太地区主要国家的独家代理商，同时双方国内合作同步升级，将合作视角从冠脉介入扩大到神经介入和外周介入领域。蓝帆医疗获国产OCT头部企业沃福曼亚太地区独家代理，国内合作同步升级 06 陶氏化学：重塑健康： 3月25日-27日，在上海新国际博览中心拉开帷幕的2026慕尼黑上海电子生产设备展（productronica China）上，陶氏公司面向“AI数智时代”下的多元高新技术领域，带来一系列高性能有机硅解决方案，并重磅发布“DOW™ Cooling Science”及热管理材料科学实验室。慕展高光时刻回顾！丨陶氏公司以热管理材料科学破解算力挑战 07 妙顺生物：合规服务：妙顺生物与国内众多医院建立了紧密的合作关系，积累了丰富的经验和资源，凭借多年的行业经验、专业的团队和严格的服务流程，全面确保在合规审批、供体招募、样本采集及运输等各个环节的合规性和可追溯性，更高效、合规地获取和利用人类遗传资源。免疫细胞全套解决方案 08 宜明昂科： III期临床： 2026年3月30日 —— 宜明昂科生物医药技术（上海）股份有限公司宣布，公司自主研发的、同时靶向CD47和CD20的双特异性抗体-受体重组蛋白药物阿沐瑞芙普α（IMM0306），联合来那度胺治疗复发/难治性滤泡性淋巴瘤（R/R FL）的III期临床研究，已成功完成首例受试者给药（FPI），正式进入关键临床阶段。宜明昂科阿沐瑞芙普α(IMM0306)治疗复发/难治性滤泡性淋巴瘤III期临床研究正式启动，首例受试者成功入组 09 银诺医药：重塑健康：银诺医药最新研究数据显示，其自主研发的长效GLP-1受体激动剂依苏帕格鲁肽α在实现显著减重的同时，能显著优化体成分结构，提高“肌肉-脂肪比”，并显著降低肝脂含量，为肥胖及代谢性疾病治疗提供了新的临床价值支撑。不止减重，更重塑代谢健康：依苏帕格鲁肽α显著改善体成分与肝脂肪 10 原能细胞：全新蓝图： 2026年4月1日，福建原能细胞科技有限公司揭牌仪式在漳州圆山医院内隆重举行，正式宣告漳州细胞产业平台项目启动，迈出打造区域生物经济高地的关键一步。擘画健康漳州新蓝图！福建原能细胞正式揭牌，启幕生物经济新时代欢迎各会员单位扫码投稿

2026-04-02

·同花顺

格博生物获赛诺菲3000万美元战略投资分子胶药物研发迎来里程碑合作

据药明康德（603259）消息，2026年2月12日，格博生物宣布获得赛诺菲3000万美元战略股权投资。此次合作将加速其分子胶药物管线的研发进程，为全球患者带来新的治疗希望。公司创始人、董事长兼首席执行官卢刚博士表示，此次合作是“天时、地利、人和的完美契合”，将助力公司在未来三年内启动多项二期临床研究及新药临床试验申请。核心优势：扎实的产品数据与理性设计能力格博生物自2021年创立之初便聚焦于分子胶降解剂的研发。分子胶技术被视为解决“不可成药”靶点难题的重要方向，其通过诱导E3连接酶标记并降解目标蛋白发挥作用，具有广阔的开发潜力。卢刚博士早在2013年便在《科学》期刊上发表了阐明来那度胺分子胶作用机制的里程碑论文，奠定了团队在该领域的深厚积累。基于十余年经验，公司建立了专有的Glue Degrader Discovery（GDD ）核心技术平台，形成了一体化研发体系。关键进展：两款在研药物获国际巨头青睐此次获得赛诺菲青睐的GLB-005和GLB-007，是两款靶向转录因子WIZ的在研分子胶项目，针对镰状细胞病等疾病领域。卢刚博士强调，尽管市场存在同类在研管线，但格博生物凭借其分子选择性、安全性等关键指标上的潜力以及扎实的研发数据赢得了合作。他认为这两款产品具备“同类最佳”潜力，有望解决未满足的临床需求。合作生态：携手伙伴共促研发卢刚博士特别强调了与合作伙伴协同的重要性。公司自创立起便与药明康德及其子公司合全药业在化学合成等方面保持深度合作，即使在疫情期间也保障了项目进度。这种紧密协作使得格博生物能更专注于其核心的科学探索与药物设计。未来展望：拓展分子胶药物的边界对于未来，卢刚博士充满信心。他认为，随着分子文库多样性增加及人工智能等技术的深度应用，分子胶药物有望降解几乎所有疾病相关蛋白，该领域的边界正在不断拓宽。格博生物将继续依托其深厚的“know-how”与成功经验，在资源支持下推进真正的创新药物研发，为患者带来切实改变。原文：里程碑合作背后：格博生物与分子胶的星辰大海｜专访卢刚博士丨Bilingual（来源：药明康德）关注同花顺财经（ths518），获取更多机会

2026-04-02

·快乐的那些事

双鹭药业7天4板：GLP-1风口下，老药企的逆袭能走多远？

4月2日，双鹭药业（002038）再度封死涨停，收盘价8.55元，涨幅10.04%，7个交易日拿下4个涨停，成交额15.1亿，换手率超21%，资金抢筹的架势一目了然。这波行情不是凭空炒起来的，核心是踩中了当下最火的减肥药GLP-1风口，再加上老药企多年的管线储备终于到了兑现期，情绪和预期一起拉满了。一、这波涨停，到底炒的是什么？很多人只知道它涨停，却没搞懂背后的实锤逻辑，先把最核心的驱动因素说透：1. 直接引爆：GLP-1减肥药管线，踩中超级风口这是本轮上涨最核心的催化剂。公司的GLP-1-Fc融合蛋白（长效周制剂）已经完成全部临床试验，正式提交了上市注册申请，同时还在布局口服GLP-1类似物Diapin，直接对标司美格鲁肽这类爆款减肥药。要知道，GLP-1是当下医药圈最火的赛道，不管是减肥药还是糖尿病，都是百亿级的大市场，只要管线有进展，资金就愿意给估值。2. 不止GLP-1：多款创新药同步申报，研发进度超预期除了GLP-1，公司还有两款重磅产品同步提交了注册：• 长效FSH（辅助生殖领域）：直接切入辅助生殖这个高景气赛道；• 聚乙二醇化粒细胞刺激因子（升白针）：肿瘤患者刚需用药，市场空间大。三款产品同时进入收获期，彻底打破了市场对双鹭“只靠老药、没新东西”的刻板印象，资金自然愿意进场。3. 基本盘托底：独家品种+稳定现金流，不是纯题材公司手里有国内独家剂型的硝酸甘油喷雾剂，已经获批上市并纳入国家医保，急救用药刚需属性强，上市后快速上量，能稳定贡献业绩。同时，公司25款产品中标国家集采，替莫唑胺、来那度胺等肿瘤药常年稳定销售，现金流非常健康，这么多年累计分红是募资的10倍，完全没有资金压力，能持续给创新药研发输血。4. 资金接力：机构调研+游资抱团，赚钱效应拉满3月26日机构集中调研，公司披露了创新药的最新进展后，机构和游资合力抢筹，连续涨停形成了极强的赚钱效应，吸引了更多资金进场接力。⚠️ 先给大家提个醒：目前GLP-1只是提交了注册申请，还没获批上市，没有商业化订单，这波上涨是预期驱动，不是业绩驱动，别盲目追高。二、双鹭药业，到底有什么真东西？核心优势，一眼看懂1. 老药稳现金流，新药高弹性以肿瘤药、心脑血管老药做基本盘，稳定赚钱反哺创新药研发，形成了完美的闭环，不用像很多创新药企那样靠融资烧钱，抗风险能力极强。2. 赛道布局精准，全是高景气方向GLP-1减肥药、辅助生殖、肿瘤、心脑血管，每一个都是当下的黄金赛道，管线布局完全踩中了市场风口，弹性拉满。3. 差异化竞争，避开价格战主打独家剂型、长效制剂，比如硝酸甘油喷雾剂国内独一份，不用跟同行打价格战，毛利率常年稳定在60%以上，远超行业平均水平。三、未来能走多远？机会和风险都给你说透最大的机会：GLP-1获批，就是估值天花板如果GLP-1周制剂顺利获批，双鹭就能直接切入百亿级的减肥药/糖尿病市场，这是公司最大的业绩弹性，也是股价最核心的上涨动力。除此之外，辅助生殖、升白针等产品获批后，2027年就能贡献业绩，带动公司彻底反转。必须警惕的风险1. 研发进度不及预期：GLP-1审批周期长，一旦获批延迟，股价很容易大幅回调；2. 赛道竞争太激烈：GLP-1玩家太多，获批后要面对原研药、仿制药的双重竞争，商业化难度不小；3. 情绪退潮风险：当前上涨全靠预期，没有实际业绩支撑，一旦资金离场，股价波动会非常剧烈；4. 集采影响：老药集采降价可能压缩利润，影响现金流。最后说句实在话双鹭药业这波上涨，是GLP-1风口+创新药管线兑现+老药企基本盘托底的结果，管线是真的，基本面是稳的，但当前完全是预期驱动，GLP-1还没获批、没有实际订单，属于高弹性的波段机会，绝对不适合追高重仓。后续重点盯两个节点：一是GLP-1的审批进度，二是公司的业绩是否能真正兑现，这两个才是决定这波行情能走多远的关键。本文仅为企业技术与行业逻辑客观分析，不构成任何投资建议，股市有风险，投资需谨慎

100 项与来那度胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04687	来那度胺	L04AX04	DB00480

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
大B细胞淋巴瘤	美国	Seagen, Inc.	2025-02-11
边缘区B细胞淋巴瘤	美国	Bristol Myers Squibb Co.	2019-05-28
成人T细胞白血病/淋巴瘤	日本	Bristol-Myers Squibb KK	2017-03-02
染色体5q缺失综合征	欧盟	Bristol-Myers Squibb Pharma EEIG	2007-06-14
染色体5q缺失综合征	冰岛	Bristol-Myers Squibb Pharma EEIG	2007-06-14
染色体5q缺失综合征	列支敦士登	Bristol-Myers Squibb Pharma EEIG	2007-06-14
染色体5q缺失综合征	挪威	Bristol-Myers Squibb Pharma EEIG	2007-06-14
滤泡性淋巴瘤	欧盟	Bristol-Myers Squibb Pharma EEIG	2007-06-14
滤泡性淋巴瘤	冰岛	Bristol-Myers Squibb Pharma EEIG	2007-06-14
滤泡性淋巴瘤	列支敦士登	Bristol-Myers Squibb Pharma EEIG	2007-06-14
滤泡性淋巴瘤	挪威	Bristol-Myers Squibb Pharma EEIG	2007-06-14
套细胞淋巴瘤	欧盟	Bristol-Myers Squibb Pharma EEIG	2007-06-14
套细胞淋巴瘤	冰岛	Bristol-Myers Squibb Pharma EEIG	2007-06-14
套细胞淋巴瘤	列支敦士登	Bristol-Myers Squibb Pharma EEIG	2007-06-14
套细胞淋巴瘤	挪威	Bristol-Myers Squibb Pharma EEIG	2007-06-14
输血依赖性贫血	欧盟	Bristol-Myers Squibb Pharma EEIG	2007-06-14
输血依赖性贫血	冰岛	Bristol-Myers Squibb Pharma EEIG	2007-06-14
输血依赖性贫血	列支敦士登	Bristol-Myers Squibb Pharma EEIG	2007-06-14
输血依赖性贫血	挪威	Bristol-Myers Squibb Pharma EEIG	2007-06-14
多发性骨髓瘤	美国	Bristol Myers Squibb Co.	2006-06-29

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
T细胞/组织细胞丰富的大B细胞淋巴瘤	临床3期	美国	Incyte Corp.	2021-05-11
T细胞/组织细胞丰富的大B细胞淋巴瘤	临床3期	日本	Incyte Corp.	2021-05-11
T细胞/组织细胞丰富的大B细胞淋巴瘤	临床3期	阿根廷	Incyte Corp.	2021-05-11
T细胞/组织细胞丰富的大B细胞淋巴瘤	临床3期	澳大利亚	Incyte Corp.	2021-05-11
T细胞/组织细胞丰富的大B细胞淋巴瘤	临床3期	奥地利	Incyte Corp.	2021-05-11
T细胞/组织细胞丰富的大B细胞淋巴瘤	临床3期	加拿大	Incyte Corp.	2021-05-11
T细胞/组织细胞丰富的大B细胞淋巴瘤	临床3期	哥伦比亚	Incyte Corp.	2021-05-11
T细胞/组织细胞丰富的大B细胞淋巴瘤	临床3期	捷克	Incyte Corp.	2021-05-11
T细胞/组织细胞丰富的大B细胞淋巴瘤	临床3期	法国	Incyte Corp.	2021-05-11
T细胞/组织细胞丰富的大B细胞淋巴瘤	临床3期	德国	Incyte Corp.	2021-05-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03477539 (CTgov)	临床2期	多发性骨髓瘤	49	Lenalidomide+Autologous Hematopoietic Stem Cell Transplantation+Daratumumab	齋積願鬱鹹淵衊鹽顧鬱 = 顧膚襯鑰獵糧窪膚獵願觸範遞製鏇選鹽蓋艱襯 (艱衊簾繭獵製衊積壓壓, 願憲夢襯鬱觸築築鬱齋 ~ 壓鹽簾繭製製網簾襯鏇) 更多	-	2026-03-09
NCT01919086 (CTgov)	临床2期	多发性骨髓瘤	30	Lenalidomide+Bortezomib+Dexamethasone	簾憲蓋獵簾夢齋廠襯鬱 = 顧構繭醖襯夢願壓鑰蓋顧鬱蓋糧膚蓋壓醖遞築 (遞製膚襯艱餘範鏇蓋網, 鏇齋齋繭鏇繭願窪襯廠 ~ 鏇艱膚廠範夢鏇鏇鬱糧) 更多	-	2026-03-02
Tandem Meetings ASTCT and CIBMTR2026	N/A	多发性骨髓瘤巩固 \| 维持	179	CAR-T consolidation	鏇簾選範築襯遞鏇膚鏇(蓋鬱積獵淵範鑰鬱壓淵) = 範觸膚鑰遞鑰醖壓鑰網鑰鹹簾鹹鹽糧觸衊壓觸 (廠膚積觸獵遞製壓鹽淵 ) 更多	不佳	2026-02-04
				Lenalidomide maintenance	鏇鹹糧鑰憲餘積願襯鬱(壓蓋簾夢顧糧鏇顧製蓋) = 廠淵獵顧壓構廠繭積選糧壓繭網淵繭願廠憲鏇 (繭廠窪夢餘鏇廠壓襯餘 ) 更多
Tandem Meetings ASTCT and CIBMTR2026	N/A	多发性骨髓瘤	71	Daratumumab+Bortezomib+Lenalidomide+Dexamethasone	製範艱衊選淵襯鏇齋鹽(獵簾願積淵觸鏇繭範顧) = 衊觸窪積餘襯鹹艱觸淵構餘網顧憲壓鑰鬱簾廠 (鹽鹽衊醖鏇顧襯選網蓋 ) 更多	积极	2026-02-04
				Daratumumab+Bortezomib+Lenalidomide+Dexamethasone (2025 IMS/IMWG high-risk criteria)	製範艱衊選淵襯鏇齋鹽(獵簾願積淵觸鏇繭範顧) = 構觸壓構製選製繭繭窪構餘網顧憲壓鑰鬱簾廠 (鹽鹽衊醖鏇顧襯選網蓋 ) 更多
Tandem Meetings ASTCT and CIBMTR2026	N/A	多发性骨髓瘤	140	Daratumumab+ bortezomib/cafilzomib+ lenalidomide+ dexamethasone (CD34+ cells <5×10^6/kg)	鬱獵壓鏇淵願選鏇鏇夢(廠餘蓋醖網獵願積窪齋) = 糧範構製壓衊鏇淵夢憲艱壓齋醖鏇壓醖獵網壓 (繭憲餘蓋夢糧積夢糧範 ) 更多	积极	2026-02-04
				Daratumumab+ bortezomib/cafilzomib+ lenalidomide+ dexamethasone (CD34+ cells ≥5×10^6/kg)	鬱獵壓鏇淵願選鏇鏇夢(廠餘蓋醖網獵願積窪齋) = 獵築夢膚齋鬱鏇網廠餘艱壓齋醖鏇壓醖獵網壓 (繭憲餘蓋夢糧積夢糧範 ) 更多
NCT02389517 (CTgov)	临床2期	多发性骨髓瘤 \| 残留肿瘤	42	Lenalidomide+Ixazomib Citrate+Dexamethasone (Arm I (Ixazomib Citrate, Lenalidomide, Dexamethasone))	遞積淵餘壓糧衊願鏇鏇 = 夢壓糧構夢願艱襯鏇鬱鬱鹹夢齋鏇壓蓋衊選築 (繭廠衊齋憲壓鑰艱網蓋, 窪淵鬱鏇製艱夢鬱夢鹹 ~ 構觸餘獵鏇鏇蓋鹽膚鏇) 更多	-	2026-01-22
				Lenalidomide (Arm II (Lenalidomide))	遞積淵餘壓糧衊願鏇鏇 = 餘獵鹽鑰夢醖膚築膚淵鬱鹹夢齋鏇壓蓋衊選築 (繭廠衊齋憲壓鑰艱網蓋, 齋壓夢蓋襯願鏇齋齋製 ~ 選簾簾鏇繭憲膚網觸艱) 更多
NCT05032820 (BMTCTN1902, CTgov)	临床2期	多发性骨髓瘤	40	leukapheresis+Lenalidomide+bb2121+Fludarabine+Cyclophosphamide	艱遞願鑰顧鬱壓鏇願廠 = 憲憲蓋淵廠壓願膚鏇選構鏇網範衊網網選選鏇 (醖觸顧簾積鏇艱願衊淵, 蓋壓範觸窪艱範齋鏇構 ~ 衊壓築積糧鏇膚築簾鏇) 更多	-	2026-01-12
NCT03702725 (CTgov)	临床1期	复发性多发性骨髓瘤 \| 难治性多发性骨髓瘤	14	Lenalidomide+Ibrutinib+Dexamethasone (Dose Level 1 (Starting DL))	鑰夢餘鹽膚顧齋顧築鏇 = 構鹽繭鏇齋範憲醖餘鬱醖簾蓋鏇衊壓餘網範範 (夢壓簾繭鏇願鬱鏇膚鏇, 製壓壓觸鑰遞網艱衊觸 ~ 製窪顧鏇鑰遞衊襯觸網) 更多	-	2026-01-06
				Lenalidomide+Ibrutinib+Dexamethasone (Dose Level 2)	鑰夢餘鹽膚顧齋顧築鏇 = 鏇網鏇獵壓淵餘製夢鏇醖簾蓋鏇衊壓餘網範範 (夢壓簾繭鏇願鬱鏇膚鏇, 衊鬱構膚獵範簾淵膚範 ~ 蓋壓築遞構餘膚餘繭鏇) 更多
NCT05409066 (EPCORE FL-1, Pubmed \| Lancet)	临床3期	难治性滤泡性淋巴瘤二线	488	Epcoritamab + Lenalidomide + Rituximab	簾餘簾鬱願範繭蓋願網(鏇憲壓鏇艱鑰繭壓鏇觸) = 積築蓋鏇範願夢廠壓遞築網廠餘淵餘襯築鹽願 (壓壓簾鬱膚願鏇廠鹹觸, 92 ~ 97) 更多	优效	2026-01-01
				Lenalidomide + Rituximab	簾餘簾鬱願範繭蓋願網(鏇憲壓鏇艱鑰繭壓鏇觸) = 鏇鬱觸積顧齋淵構鑰淵築網廠餘淵餘襯築鹽願 (壓壓簾鬱膚願鏇廠鹹觸, 74 ~ 84) 更多
NCT05025800 (ASH2025)	临床2期	惰性B细胞非霍奇金淋巴瘤一线	24	Evorpacept (ALX148) + Lenalidomide + Rituximab	顧網齋繭鹹夢廠衊齋繭(範鹽鬱膚夢壓膚憲醖糧) = 積繭齋艱顧憲夢構鹽蓋憲齋築齋壓鏇艱糧齋構 (鏇廠衊膚窪築壓憲鹽艱 ) 更多	积极	2025-12-06